Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 2 048 JPY -1.25% Market Closed
Market Cap: 3.7T JPY

Net Margin
Astellas Pharma Inc

6.2%
Current
4%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.2%
=
Net Income
124.9B
/
Revenue
2T

Net Margin Across Competitors

Country Company Market Cap Net
Margin
JP
Astellas Pharma Inc
TSE:4503
3.7T JPY
6%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
27%
CH
Roche Holding AG
SIX:ROG
253.1B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
16%
CH
Novartis AG
SIX:NOVN
203.4B CHF
26%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.7B USD
16%
No Stocks Found

Astellas Pharma Inc
Glance View

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

Intrinsic Value
1 902.26 JPY
Overvaluation 7%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.2%
=
Net Income
124.9B
/
Revenue
2T
What is the Net Margin of Astellas Pharma Inc?

Based on Astellas Pharma Inc's most recent financial statements, the company has Net Margin of 6.2%.

Back to Top